Alternatives to Ciprofloxacin

Primary Alternative: Levofloxacin

The Infectious Diseases Society of America recommends levofloxacin as the preferred alternative to ciprofloxacin due to its superior gram-positive coverage and equivalent or superior gram-negative coverage 1, 2
Levofloxacin has enhanced gram-positive activity, particularly against Streptococcus pneumoniae and viridans group streptococci, which ciprofloxacin lacks 1, 3
The American College of Clinical Pharmacy suggests that levofloxacin has better respiratory pathogen coverage, including atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) 3, 4

For antibacterial prophylaxis in neutropenic patients, the National Comprehensive Cancer Network strongly recommends levofloxacin if fluoroquinolone prophylaxis is planned, with a strong recommendation and moderate-quality evidence 1, 2
For gastrointestinal infections, the Infectious Diseases Society of America recommends levofloxacin 500 mg once daily orally for Salmonella (nontyphoidal) and Shigella 5, 6
For skin and soft tissue infections, the European Society of Clinical Microbiology and Infectious Diseases suggests levofloxacin or moxifloxacin (if fluoroquinolone needed) for animal bites 7, 8
For intra-abdominal infections, the Surgical Infection Society recommends amoxicillin-clavulanic acid as the first choice, avoiding fluoroquinolones 9
For community-acquired pneumonia (severe), the American Thoracic Society recommends levofloxacin 750 mg/24h or 500 mg twice daily plus non-antipseudomonal cephalosporin III for ICU patients without Pseudomonas risk 4

When fluoroquinolones must be avoided entirely, the Infectious Diseases Society of America suggests considering beta-lactam/beta-lactamase inhibitors, such as amoxicillin-clavulanic acid, ampicillin-sulbactam, and piperacillin-tazobactam 7, 8, 9
The European Society of Clinical Microbiology and Infectious Diseases recommends third-generation cephalosporins, such as ceftriaxone and cefotaxime, often with metronidazole for anaerobic coverage 9, 4
The American College of Clinical Pharmacy suggests carbapenems, such as meropenem, for severe infections or ESBL concerns 9, 4
The Infectious Diseases Society of America recommends macrolides, such as azithromycin, for specific pathogens (Campylobacter, atypical respiratory pathogens) 5, 6, 4